Description: Newbury Pharmaceuticals AB (publ), a pharmaceutical company, produces and commercializes in-licensed specialty prescription drugs in Sweden, Denmark, Norway, and other Scandinavian countries. It offers oncology drugs, such as Lenalidomide, Sunitinib, Pazopanib, Lapatinib, Bosutinib, Lenvatinib, Enzalutamide, Nilotinib, Pomalidomide, Palbociclib, and Nintedanib; drugs for rare diseases, including Icatibant, Macitentan, Pirfenidone, and Teduglutide; neurology drugs, which include dimetylfumarat, lorazepam ER, teriflunomide, and fampridine; and drugs for various other therapeutic areas comprising Solifenacin + Tamsulosin, Liraglutide, Desmopressin ODT, Gabapentin ER, Rivaroxaban, Ticagrelor, Tofacitinib, and Varenicline. The company was incorporated in 2020 and is based in Lund, Sweden.
Home Page: www.newburypharma.com
Scheeletorget 1
Lund,
223 81
Sweden
Phone:
46 46 12 11 20
Officers
| Name | Title |
|---|---|
| Mr. Karl Karlsson | Founder & Exec. Chairman |
| Mr. Christoffer Tell | Chief Financial Officer |
| Mr. Fredrik Hellqvist | VP of Sales & Marketing |
| Mr. Lars Minor | Chief Exec. Officer |
| Ms. Andrea Karnitschky | Sr. Director & Head of Bus. Devel. |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.8606 |
| Price-to-Sales TTM: | 25.0927 |
| IPO Date: | |
| Fiscal Year End: | August |
| Full Time Employees: | 4 |